Literature DB >> 33832965

Variants in urate transporters, ADH1B, GCKR and MEPE genes associate with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians using data from the UK Biobank.

Gabriela Sandoval-Plata1,2,3, Kevin Morgan3, Abhishek Abhishek4,2.   

Abstract

OBJECTIVES: To perform a genome-wide association study (GWAS) of gout cases versus asymptomatic hyperuricaemia (AH) controls, and gout cases versus normouricaemia controls, and to generate a polygenic risk score (PRS) to determine gout-case versus AH-control status.
METHODS: Gout cases and AH controls (serum urate (SU) ≥6.0 mg/dL) from the UK Biobank were divided into discovery (4934 cases, 56 948 controls) and replication (2115 cases, 24 406 controls) cohorts. GWAS was conducted and PRS generated using summary statistics in discovery cohort as the base dataset and the replication cohort as the target dataset. The predictive ability of the model was evaluated. GWAS were performed to identify variants associated with gout compared with normouricaemic controls using SU <6.0 mg/dL and <7.0 mg/dL thresholds, respectively.
RESULTS: Thirteen independent single nucleotide polymorphisms (SNPs) in ABCG2, SLC2A9, SLC22A11, GCKR, MEPE, PPM1K-DT, LOC105377323 and ADH1B reached genome-wide significance and replicated as predictors of AH to gout transition. Twelve of 13 associations were novel for this transition, and rs1229984 (ADH1B) was identified as GWAS locus for gout for the first time. The best PRS model was generated from association data of 17 SNPs; and had predictive ability of 58.5% that increased to 69.2% on including demographic factors. Two novel SNPs rs760077(MTX1) and rs3800307(PRSS16) achieved GWAS significance for association with gout compared with normouricaemic controls using both SU thresholds.
CONCLUSION: The association of urate transporters with gout supports the central role of hyperuricaemia in its pathogenesis. Larger GWAS are required to identify if variants in inflammatory pathways contribute to progression from AH to gout. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  arthritis; crystal arthropathies; gout

Mesh:

Substances:

Year:  2021        PMID: 33832965     DOI: 10.1136/annrheumdis-2020-219796

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  12 in total

1.  Microbiome-associated human genetic variants impact phenome-wide disease risk.

Authors:  Robert H George Markowitz; Abigail Leavitt LaBella; Mingjian Shi; Antonis Rokas; John A Capra; Jane F Ferguson; Jonathan D Mosley; Seth R Bordenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-24       Impact factor: 12.779

2.  Mapping Knowledge Structure and Global Research Trends in Gout: A Bibliometric Analysis From 2001 to 2021.

Authors:  Pengfei Wen; Pan Luo; Binfei Zhang; Yumin Zhang
Journal:  Front Public Health       Date:  2022-06-29

3.  Examining an Association of Single Nucleotide Polymorphisms with Hyperuricemia in Chinese Flight Attendants.

Authors:  Jianpin Ye; Zhiwei Zeng; Yuxian Chen; Zhenkun Wu; Qingwei Yang; Tao Sun
Journal:  Pharmgenomics Pers Med       Date:  2022-06-08

Review 4.  Trends in the Contribution of Genetic Susceptibility Loci to Hyperuricemia and Gout and Associated Novel Mechanisms.

Authors:  Jianan Zhao; Shicheng Guo; Steven J Schrodi; Dongyi He
Journal:  Front Cell Dev Biol       Date:  2022-06-23

Review 5.  Uric acid extrarenal excretion: the gut microbiome as an evident yet understated factor in gout development.

Authors:  Eder Orlando Méndez-Salazar; Gabriela Angélica Martínez-Nava
Journal:  Rheumatol Int       Date:  2021-09-29       Impact factor: 2.631

6.  Are polymorphisms affecting serum urate, renal urate handling and alcohol intake associated with co-morbidities in gout cases? A case-control study using data from the UK Biobank.

Authors:  Gabriela Sandoval-Plata; Kevin Morgan; Abhishek Abhishek
Journal:  Rheumatol Int       Date:  2022-05-28       Impact factor: 3.580

7.  Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum.

Authors:  Georgina Nakafero; Matthew J Grainge; Tim Card; Maarten W Taal; Guruprasad P Aithal; Weiya Zhang; Michael Doherty; Christopher P Fox; Christian D Mallen; Abhishek Abhishek
Journal:  Rheumatology (Oxford)       Date:  2022-07-06       Impact factor: 7.046

Review 8.  A glance into the future of gout.

Authors:  Francisca Sivera; Mariano Andres; Nicola Dalbeth
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-07-28       Impact factor: 3.625

Review 9.  Susceptibility genes of hyperuricemia and gout.

Authors:  Yue-Li Nian; Chong-Ge You
Journal:  Hereditas       Date:  2022-08-04       Impact factor: 2.595

Review 10.  Genetics of hyperuricemia and gout: Insights from recent genome-wide association studies and Mendelian randomization studies.

Authors:  Yu-Lin Ko
Journal:  Tzu Chi Med J       Date:  2021-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.